METHODS: In Erciyes University Bone Marrow Transplantation Unit, 218 patients who underwent apheresis for stem cell mobilization between 2011 and 2021 were evaluated retrospectively. One hundred and nine patients had a diagnosis of DM, and 109 did not.
RESULTS: Mobilization failure developed in 17 (15.6 %) of the patients in the DM group, while it developed in 7 (6.4 %) patients in the non-DM group (p = 0.03). CD34+ stem cell count was 8.05 (1.3-30.2) × 106/kg in the DM group, while it was 8.2 (1.7-37.3) × 106/kg in the other group (p = 0.55). There was no statistically significant relationship between glucose and hemoglobin A1c levels and the amount of CD34+ cells (p = 0.83 and p = 0.14, respectively). Using sulfonylurea was the only independent predictor of mobilization failure (OR 5.75, 95 % CI: 1.38-24.05, p = 0.02).
CONCLUSIONS: DM should be considered a risk factor for mobilization failure. Further research is needed fully to understand the mechanisms underlying the mobilization failure effects of sulfonylureas and to develop strategies to improve stem cell mobilization in diabetic patients.
方法:在Erciyes大学骨髓移植单元,对2011年至2021年间接受单采术进行干细胞动员的218例患者进行了回顾性评估。109名患者被诊断为DM,109没有。
结果:DM组17例(15.6%)患者出现动员失败,而在非DM组中有7例(6.4%)患者出现(p=0.03)。DM组CD34+干细胞计数为8.05(1.3-30.2)×106/kg,而另一组为8.2(1.7-37.3)×106/kg(p=0.55)。在葡萄糖和血红蛋白A1c水平与CD34+细胞的数量之间没有统计学上显著的关系(分别为p=0.83和p=0.14)。使用磺酰脲是动员失败的唯一独立预测因子(OR5.75,95%CI:1.38-24.05,p=0.02)。
结论:DM应被视为动员失败的危险因素。需要进一步的研究来充分了解磺脲类药物动员失败效应的潜在机制,并制定改善糖尿病患者干细胞动员的策略。